Inflammatory signatures and immunomodulation in neonates: a pilot study.
Our pilot results strongly encourage further investigations comparing age groups and different immunomodulatory agents further promoting the discussion that TLR7/8 ligands could be suitable vaccine adjuvant candidates for newborns. At the same time, IL-10-associated immunomodulation (monoclonal antibody anti-IL-10, anti-IL-10 receptors, or anti-TLR1/2) might be a future therapeutic option for cases of overwhelming neonatal inflammatory diseases.
Authors
- Marzia Duse (ORCID: https://orcid.org/0000-0001-9958-2570)
- Luigi Tarani (ORCID: https://orcid.org/0000-0001-5958-9364)
- Marco Fiore (ORCID: https://orcid.org/0000-0001-7263-0229)
- Alberto Spalice (ORCID: https://orcid.org/0000-0002-8455-796X)
- Lucia Leonardi (ORCID: https://orcid.org/0000-0002-2554-1263)
- Rossella Laitano
- Franca Natale (ORCID: https://orcid.org/0000-0002-4099-3233)
- Elisabeth Förster‐Waldl (ORCID: https://orcid.org/0000-0002-8484-9890)
- Rita Carsetti (ORCID: https://orcid.org/0000-0002-2632-1078)
- Valentina Pennetta
Institutions
- University of Rome Tor Vergata (IT)
- Institute of Cell Biology and Neurobiology (IT)
- Medical University of Vienna (AT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- PubMed
- Published
- 2025-06-17
- DOI
- https://doi.org/10.7417/ct.2025.5233
- Primary Topic
- Neonatal Respiratory Health Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00